JP2005529927A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005529927A5 JP2005529927A5 JP2004506721A JP2004506721A JP2005529927A5 JP 2005529927 A5 JP2005529927 A5 JP 2005529927A5 JP 2004506721 A JP2004506721 A JP 2004506721A JP 2004506721 A JP2004506721 A JP 2004506721A JP 2005529927 A5 JP2005529927 A5 JP 2005529927A5
- Authority
- JP
- Japan
- Prior art keywords
- hypertension
- inhibitor
- methyl
- pde5
- sildenafil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 8
- 206010020772 Hypertension Diseases 0.000 claims 6
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 5
- -1 4-methyl-1-piperazinylsulfonyl Chemical group 0.000 claims 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 4
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229960003310 sildenafil Drugs 0.000 claims 4
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims 4
- 229960002769 zofenopril Drugs 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- LOVMAMBYUGCUIX-UHFFFAOYSA-N 1-methyl-3-propyl-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound N1=CNC(=O)C2=C1C(CCC)=NN2C LOVMAMBYUGCUIX-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 201000004239 Secondary hypertension Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042957 Systolic hypertension Diseases 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 229960002639 sildenafil citrate Drugs 0.000 claims 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0211919A GB0211919D0 (en) | 2002-05-23 | 2002-05-23 | Novel combination |
| GB0229784A GB0229784D0 (en) | 2002-12-20 | 2002-12-20 | Novel combination |
| PCT/IB2003/001889 WO2003099194A2 (en) | 2002-05-23 | 2003-05-09 | Pharmaceutical combination of pde5 inhibitors with ace inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005529927A JP2005529927A (ja) | 2005-10-06 |
| JP2005529927A5 true JP2005529927A5 (https=) | 2006-06-15 |
Family
ID=29585817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004506721A Abandoned JP2005529927A (ja) | 2002-05-23 | 2003-05-09 | 新規な組み合わせ |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1506015A2 (https=) |
| JP (1) | JP2005529927A (https=) |
| KR (1) | KR20050004195A (https=) |
| CN (1) | CN1655820A (https=) |
| AR (1) | AR040090A1 (https=) |
| AU (1) | AU2003223071A1 (https=) |
| BR (1) | BR0311191A (https=) |
| CA (1) | CA2485984A1 (https=) |
| IL (1) | IL164975A0 (https=) |
| MX (1) | MXPA04010951A (https=) |
| NO (1) | NO20045517L (https=) |
| PA (1) | PA8574201A1 (https=) |
| PE (1) | PE20040514A1 (https=) |
| PL (1) | PL374198A1 (https=) |
| RU (1) | RU2004133973A (https=) |
| TW (1) | TW200407153A (https=) |
| UY (1) | UY27816A1 (https=) |
| WO (1) | WO2003099194A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
| GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
| EP1579862A1 (en) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
| US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
| FR2902009B1 (fr) * | 2006-06-13 | 2012-12-07 | Bioprojet Soc Civ | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire |
| JP2010501577A (ja) | 2006-08-24 | 2010-01-21 | サーフェイス ロジックス，インコーポレイティド | 薬物動態が改善された化合物 |
| EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
| EP3167876B1 (en) | 2012-03-15 | 2021-09-08 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
| EP3021832B9 (en) | 2013-07-19 | 2023-03-15 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
| CA2930033C (en) | 2013-12-04 | 2022-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
| US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
| GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| US6362178B1 (en) * | 1997-11-12 | 2002-03-26 | Bayer Aktiengesellschaft | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| AP2002002455A0 (en) * | 1999-10-11 | 2002-06-30 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors. |
-
2003
- 2003-05-09 CN CNA038118262A patent/CN1655820A/zh active Pending
- 2003-05-09 BR BR0311191-1A patent/BR0311191A/pt not_active IP Right Cessation
- 2003-05-09 KR KR10-2004-7018868A patent/KR20050004195A/ko not_active Abandoned
- 2003-05-09 JP JP2004506721A patent/JP2005529927A/ja not_active Abandoned
- 2003-05-09 EP EP03719042A patent/EP1506015A2/en not_active Withdrawn
- 2003-05-09 MX MXPA04010951A patent/MXPA04010951A/es unknown
- 2003-05-09 AU AU2003223071A patent/AU2003223071A1/en not_active Abandoned
- 2003-05-09 PL PL03374198A patent/PL374198A1/xx not_active Application Discontinuation
- 2003-05-09 WO PCT/IB2003/001889 patent/WO2003099194A2/en not_active Ceased
- 2003-05-09 CA CA002485984A patent/CA2485984A1/en not_active Abandoned
- 2003-05-09 RU RU2004133973/15A patent/RU2004133973A/ru not_active Application Discontinuation
- 2003-05-12 TW TW092112826A patent/TW200407153A/zh unknown
- 2003-05-19 PE PE2003000482A patent/PE20040514A1/es not_active Application Discontinuation
- 2003-05-21 AR ARP030101762A patent/AR040090A1/es unknown
- 2003-05-21 UY UY27816A patent/UY27816A1/es not_active Application Discontinuation
- 2003-05-22 PA PA20038574201A patent/PA8574201A1/es unknown
-
2004
- 2004-11-01 IL IL16497504A patent/IL164975A0/xx unknown
- 2004-12-17 NO NO20045517A patent/NO20045517L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005529927A5 (https=) | ||
| NO2008013I2 (no) | Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt, særlig monofosfatet, pluss metformin hydroklorid. | |
| CA2749730C (en) | Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction | |
| JP2007511487A5 (https=) | ||
| JP2005041875A5 (https=) | ||
| JP2008515905A5 (https=) | ||
| JP2017523219A5 (https=) | ||
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| WO2015011086A1 (en) | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis | |
| KR20070111539A (ko) | 진성 당뇨병 치료용 로플루밀라스트 | |
| JP2009518415A5 (https=) | ||
| JP2005531627A5 (https=) | ||
| RU2004133973A (ru) | Новая комбинация | |
| WO2007054514A3 (en) | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure | |
| HUP0300477A2 (hu) | A PDE5 inhibitorokat tartalmazó készítmények alkalmazása az erekciós zavarok napi kezelésére | |
| JP2004510775A5 (https=) | ||
| JP2007512317A (ja) | ピラゾロピリミジン類 | |
| RU2004136276A (ru) | Комбинация ингибиторов фдэ5 с антагонистами рецепторов ангиотензина 11 | |
| HUP0204097A2 (hu) | Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására | |
| WO2005011727A1 (en) | Combination of an activator of soluble guanylate cyclase and an ace-inhibitor for the treatment of a cardiovascular or metabolic disorder | |
| US6271228B1 (en) | Blood pressure stabilization during hemodialysis | |
| WO2005042022A2 (en) | Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist | |
| US20040077624A1 (en) | Novel combination | |
| JPWO2022106711A5 (https=) | ||
| RU2011105465A (ru) | 2-гидрокси-этансульфонатная соль |